ArticleFrontiers in public health2025
A GBD 2021 study of Alzheimer's disease and other dementias attributable to metabolic risk factors and forecasts to 2045 in China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends and forecasts of the prevalence and mortality of Alzheimer's disease and other dementias in China.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: High fasting plasma glucose (FPG) and body mass index (BMI) are recognized as significant metabolic risk factors for Alzheimer's disease (AD) and other dementias. This study assesses the burden of AD and other dementias attributable to these risks in China using Global Burden of Disease (GBD) 2021 data. Methods: We estimated deaths, disability-adjusted life-years (DALYs), years lived with disability (YLDs), and age-standardized rates of mortality (ASMR), DALYs (ASDR), and YLDs (ASYR) by age and sex. Temporal trends were analyzed via the average annual percentage change (AAPC), and Bayesian age-period-cohort (BAPC) models were applied to evaluate the effects of age, period, and cohort. Results: In 2021, China recorded 76,239.36 deaths (95% UI: 2,528.26-259,225.86) from AD and other dementias due to metabolic risks, a 4.7-fold increase from 1990. Females experienced more metabolic risk-related deaths [51,844.08 (95% UI, 1,457.44, 177,037.05)] than males. The ASMR, ASDR, and ASYR showed continuous increases from 1990 to 2021, with AAPC values of 1.03, 1.31, and 1.98%, respectively. A significant increasing trend was observed across age groups from 40 to 95 years, with percentages above 0. Females presented relatively higher risks than males after 1997-2001 and within the birth cohort groups of 1957-1966. The disease burden due to HBMI is expected to rise, while that due to HFPG will decline, notable sex will persist until 2045. Conclusion: Monitoring trends is crucial for interventions to reduce the future disease burden, particularly among women and older populations in China, to guide healthcare resource allocation effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.